Cite
HARVARD Citation
Kister, I. et al. (2022). Cellular and Humoral Immunity to SARS‐CoV‐2 Infection in Multiple Sclerosis Patients on Ocrelizumab and Other Disease‐Modifying Therapies: A Multi‐Ethnic Observational Study. Annals of neurology. 91 (6), pp. 782-795. [Online].